SHERIDAN, WYOMING – May 8, 2025 – Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, has announced a significant $2 billion investment over the next four years, aimed at enhancing U.S. innovation and manufacturing across the life sciences sector. This strategic investment underscores Thermo Fisher's continued confidence in America's ability to lead global scientific advancement while further supporting biopharma companies in the development and production of life-saving medicines.
Strengthening U.S. Manufacturing Infrastructure
The bulk of the $2 billion investment, amounting to $1.5 billion, will be allocated toward expanding and upgrading Thermo Fisher’s U.S.-based manufacturing operations. This move not only solidifies the company's already strong presence in the U.S. but also positions it as a key player in maintaining a resilient healthcare supply chain.
Thermo Fisher operates 64 manufacturing facilities across 37 U.S. states, producing analytical instruments, specialty diagnostics, and life sciences solutions. This expansive network of operations forms the backbone of the company’s strategy to support biopharma clients in delivering essential therapies to the market.
Fostering Innovation with $500 Million R&D Investment
Complementing the capital expenditures, Thermo Fisher is committing $500 million to research and development (R&D), aimed at driving high-impact innovation in life sciences and healthcare. This R&D push reflects the company’s ongoing efforts to stay at the forefront of scientific discovery and technological advancement.
“We are proud to be part of a vibrant, growing American economy,” said Marc N. Casper, Chairman, President, and CEO of Thermo Fisher Scientific. “Our commitment to expanding U.S. manufacturing reflects our confidence that America will continue to lead the world in science and innovation. By increasing our domestic operations, we ensure that life-saving medicines and therapies will continue to be developed and produced in America for decades to come.”
Expanding Workforce and Creating High-Paying Jobs
Thermo Fisher's commitment to U.S. innovation is not limited to its facilities and infrastructure; it also translates into a stronger workforce. Since 2017, the company has more than doubled its size, growing its U.S. employee base from 28,000 to over 50,000. As part of its continued expansion, Thermo Fisher plans to create additional high-paying jobs, further contributing to the U.S. economy and supporting local communities.
With annual investments of over $1 billion in U.S. R&D, Thermo Fisher’s ongoing expansion reflects its dedication to both economic growth and technological leadership. By scaling operations and increasing research capacity, the company is positioned to continue supporting biopharma innovators and ensuring the U.S. remains a hub for scientific breakthroughs.
Strategic Impact and Future Growth
Thermo Fisher's investment comes at a time when global demand for advanced manufacturing and life sciences solutions is rising rapidly. With biopharma companies increasingly turning to U.S.-based facilities for the production of critical medicines, Thermo Fisher’s expanded operations will play a pivotal role in supporting a secure and competitive healthcare supply chain.
The company’s ongoing growth exemplifies its role as a driving force in the American economy, reinforcing the nation’s position as a leader in global scientific and manufacturing sectors.
For more information on Thermo Fisher Scientific and its operations, visit www.thermofisher.com.